Neurocrine Biosciences, Inc.
NBIX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.77B
Close$
$429.64
158.7% upside
Current Fair Value
158.7% upsideUndervalued by 158.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $16.77 Billion |
|---|---|
| Enterprise Value | $17.17 Billion |
| Earnings per Share | $4.81 |
| Beta | 0.4 |
| Outstanding Shares | 101,000,000 |
Return
| Return on Equity | 17.68% |
|---|---|
| Return on Assets | 13.16% |
| Return on Invested Capital | 17.56% |
Valuation & Multiples
| P/E Ratio | 20.72 |
|---|---|
| PEG | 60.37 |
| Price to Sales | 5.03 |
| Price to Book Ratio | 4.26 |
| Enterprise Value to Revenue | 5.09 |
| Enterprise Value to EBIT | 21.81 |
| Enterprise Value to Net Income | 24 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
$1.91
Consensus analyst estimateRevenue Estimate
$1.04 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 10, 2027
EPS Estimate
$2.07
Consensus analyst estimateRevenue Estimate
$1.09 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 103.23% |
|---|---|
| Total Calls | 400▼ 99.90% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.26%▼ 96.24% |
|---|---|
| Total Invested | $754.45M▼ 95.61% |
| Investors Holding | 240▼ 558.00% |
About Neurocrine Biosciences, Inc.
2,000 employees
CEO: Kevin Gorman
Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for a range of neurological, endocrine, and psychiatric conditions. Its established portfol...